Christine Chevreau - Concepedia

Author

Christine Chevreau

Institut universitaire du cancer de Toulouse Oncopole ORCID

Also Known As

C Chevreau, C. Chevreau, C.M. Chevreau, CHRISTINE CHEVREAU, Christine Chevreau

204

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Institut universitaire du cancer de Toulouse Oncopole Institut Paoli-Calmettes Institut Gustave Roussy Centre Léon Bérard Assistance Publique – Hôpitaux de Paris

About

Christine Chevreau is an author at Institut universitaire du cancer de Toulouse Oncopole specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	1.4K
2	Health Sciences	3	3	66
3	Public Health	1	1	15
4	Biomedical Engineering	1	1	115
5	Cell Biology	1	1	22

Christine Chevreau

Publications

Citations

H-Index

Page 1

	Year	Citations
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas Maud Toulmonde, Nicolas Penel, Julien Adam, JAMA Oncology	2017	381
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. M Forni, M C Malet-Martino, P Jaillais, Journal of Clinical Oncology	1992	334
Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics Étienne Chatelut, Pierre Canal, Vincent Brunner, JNCI Journal of the National Cancer Institute	1995	245
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort Antoîne Italiano, Alban Bessede, M. Pulido, Nature Medicine Lymphoid NeoplasiaPembrosarc Trial CohortMedicineSoft-tissue SarcomasImmunology	2022	235
Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study Maud Toulmonde, Marina Pulido, Isabelle Ray‐Coquard, The Lancet Oncology OncologyCombination ChemotherapyMetronomic TherapyProgressive Desmoid TumoursPharmacotherapy	2019	193
Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO) Thibaud Valentin, Axel Le Cesne, Isabelle Ray‐Coquard, European Journal of Cancer Neuro-oncologySurgical OncologyTumoral PathologyTumor InnervationSurgical Pathology	2016	187
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study Ronan Flippot, Cécile Dalban, Brigitte Laguerre, Journal of Clinical Oncology	2019	157
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial Yann Vano, Réza Elaidi, Mostefa Bennamoun, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2022	128
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? Arnaud Méjean, Alain Ravaud, Simon Thézenas, European Urology UrologySurgical OncologyGenitourinary CancerMedicineCytoreductive Nephrectomy	2021	124
Electrochemotherapy of cutaneous metastases in malignant melanoma Marie‐Pierre Rols, Jean‐Marc Bachaud, P. Giraud, Melanoma Research Tumor BiologySurgical OncologyMedicineMelanomaElectrophysiology	2000	115

Page 1